Clinical Trials Browser

NCT03866382 2026-03-18

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT04071223 2026-03-18

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Phase 2 Active not recruiting

134 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04981509 2026-03-18

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Phase 2 Recruiting

65 enrolled

Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT05411081 2026-03-18

Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

Phase 2 Active not recruiting

200 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT07470840 2026-03-17

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Phase 2 Not yet recruiting

27 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04904302 2026-03-16

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

Phase 2 Terminated

15 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT06863311 2026-03-16

EXACT

Phase 2 Recruiting

70 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT03945773 2026-03-13

CaboPoint

Phase 2 Completed

127 enrolled 17 charts

Genitourinary

Carcinoma, Renal Cell

NCT06708949 2026-03-13

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

Phase 2 Recruiting

15 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT07469683 2026-03-13

An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Phase 2 Recruiting

78 enrolled

Genitourinary

Carcinoma, Renal Cell, Neoplasms

NCT07077083 2026-03-11

CAIX PET/CT

Phase 2 Not yet recruiting

10 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT07460206 2026-03-10

PRELUDE

Phase 2 Not yet recruiting

108 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT02568267 2026-03-06

STARTRK-2

Phase 2 Active not recruiting

534 enrolled 1 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT06860386 2026-03-06